PT  - JOURNAL ARTICLE
AU  - Demichev, Vadim
AU  - Tober-Lau, Pinkus
AU  - Nazarenko, Tatiana
AU  - Aulakh, Simran Kaur
AU  - Whitwell, Harry
AU  - Lemke, Oliver
AU  - Röhl, Annika
AU  - Freiwald, Anja
AU  - Mittermaier, Mirja
AU  - Szyrwiel, Lukasz
AU  - Ludwig, Daniela
AU  - Correia-Melo, Clara
AU  - Lippert, Lena J.
AU  - Helbig, Elisa T.
AU  - Stubbemann, Paula
AU  - Olk, Nadine
AU  - Thibeault, Charlotte
AU  - Grüning, Nana-Maria
AU  - Blyuss, Oleg
AU  - Vernardis, Spyros
AU  - White, Matthew
AU  - Messner, Christoph B.
AU  - Joannidis, Michael
AU  - Sonnweber, Thomas
AU  - Klein, Sebastian J.
AU  - Pizzini, Alex
AU  - Wohlfarter, Yvonne
AU  - Sahanic, Sabina
AU  - Hilbe, Richard
AU  - Schaefer, Benedikt
AU  - Wagner, Sonja
AU  - Machleidt, Felix
AU  - Garcia, Carmen
AU  - Ruwwe-Glösenkamp, Christoph
AU  - Lingscheid, Tilman
AU  - de Jarcy, Laure Bosquillon
AU  - Stegemann, Miriam S.
AU  - Pfeiffer, Moritz
AU  - Jürgens, Linda
AU  - Denker, Sophy
AU  - Zickler, Daniel
AU  - Spies, Claudia
AU  - Edel, Andreas
AU  - Müller, Nils B.
AU  - Enghard, Philipp
AU  - Zelezniak, Aleksej
AU  - Bellmann-Weiler, Rosa
AU  - Weiss, Günter
AU  - Campbell, Archie
AU  - Hayward, Caroline
AU  - Porteous, David J.
AU  - Marioni, Riccardo E.
AU  - Uhrig, Alexander
AU  - Zoller, Heinz
AU  - Löffler-Ragg, Judith
AU  - Keller, Markus A.
AU  - Tancevski, Ivan
AU  - Timms, John F.
AU  - Zaikin, Alexey
AU  - Hippenstiel, Stefan
AU  - Ramharter, Michael
AU  - Müller-Redetzky, Holger
AU  - Witzenrath, Martin
AU  - Suttorp, Norbert
AU  - Lilley, Kathryn
AU  - Mülleder, Michael
AU  - Sander, Leif Erik
AU  - ,
AU  - Kurth, Florian
AU  - Ralser, Markus
TI  - A proteomic survival predictor for COVID-19 patients in intensive care
AID  - 10.1101/2021.06.24.21259374
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.24.21259374
4099  - http://medrxiv.org/content/early/2021/06/26/2021.06.24.21259374.short
4100  - http://medrxiv.org/content/early/2021/06/26/2021.06.24.21259374.full
AB  - Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such as SOFA and APACHE II scores show only limited performance for predicting the survival of severely ill COVID-19 patients. Comprehensively capturing the host physiology, we speculated that proteomics in combination with new data-driven analysis strategies could produce a new generation of prognostic discriminators. We studied two independent cohorts of patients with severe COVID-19 who required intensive care and invasive mechanical ventilation. SOFA score, Charlson comorbidity index and APACHE II score were poor predictors of survival. Plasma proteomics instead identified 14 proteins that showed concentration trajectories different between survivors and non-survivors. A proteomic predictor trained on single samples obtained at the first time point at maximum treatment level (i.e. WHO grade 7) and weeks before the outcome, achieved accurate classification of survivors in an exploratory (AUROC 0.81) as well as in the independent validation cohort (AUROC of 1.0). The majority of proteins with high relevance in the prediction model belong to the coagulation system and complement cascade. Our study demonstrates that predictors derived from plasma protein levels have the potential to substantially outperform current prognostic markers in intensive care.Trial registration German Clinical Trials Register DRKS00021688Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00021688Funding StatementThis work was supported by the Berlin University Alliance (501-Massenspektrometrie, 501-Linklab, 112-PreEP-Corona-Ralser), by UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the BMBF/DLR Projektträger (01KI20160A, 01ZX1604B, 01KI20337, 01KX2021), Charité-BIH Centrum für Therapieforschung (BIH-PA-covid-19-Ralser), the BBSRC (BB/N015215/1, BB/N015282/1), the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001134), the UK Medical Research Council (FC001134), and the Wellcome Trust (FC001134 and IA 200829/Z/16/Z). The work was further supported by the Ministry of Education and Research (BMBF), as part of the National Research Node Mass spectrometry in Systems Medicine (MSCoresys), under grant agreement 031L0220A. Leif Erik Sander is supported by the German Research Foundation (DFG, SFB-TR84 114933180) and by the Berlin Institute of Health (BIH), which receives funding from the Ministry of Education and Research (BMBF). Martin Witzenrath is supported by grants from the German Research Foundation, SFB-TR84 C06 and C09, by the German Ministry of Education and Research (BMBF) in the framework of the CAPSyS (01ZX1304B), CAPSyS-COVID (01ZX1604B), SYMPATH (01ZX1906A) and PROVID project (01KI20160A) and by the Berlin Institute of Health (CM-COVID). Stefan Hippenstiel is supported by the German Research Foundation (DFG, SFB-TR84 A04 and B06), and the BMBF (PROVID, and project 01KI2082). Norbert Suttorp is supported by grants from the German Research Foundation, SFB-TR84 C09 und Z02, by the German Ministry of Education and Research (BMBF) in the framework of the PROGRESS 01KI07114. The study was further supported by Wellcome Trust (200829/Z/16/Z). The Generation Scotland study received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006), and is now supported by the Welcome Trust (216767/Z/19/Z). Archie Campbell is funded by HDR UK and the Wellcome Trust (216767/Z/19/Z). Caroline Hayward is supported by an MRC University Unit Programme Grant (MC-UU-00007/10) (QTL in Health and Disease). Riccardo Marioni is supported by an Alzheimer s Research UK project grant (ARUK-PG2017B-10). H. Whitwell, JF. Timms, A. Zaikin and T. Nazarenko are supported by a Medical Research Council grant (MR/R02524X/1) and H. Whitwell, A. Zaikin and O. Blyuss by the Ministry of Science and Higher Education agreement No. 075-15-2020-808. H. Whitwell is supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC). J. Timms is supported by the National Institute for Health Research (NIHR) UCLH/UCL Biomedical Research Centre. Mirja Mittermaier is a participant in the BIHCharité Digital Clinician Scientist Program funded by the Charité — Universitätsmedizin Berlin, the Berlin Institute of Health, and the German Research Foundation (DFG). Markus A. Keller is supported by the Austrian Science Funds (FWF; P33333) and the Austrian Research Promotion Agency (FFG, #878654). Figures were created with biorender.com.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Charité - Universit?auml;tsmedizin Berlin (EA2/066/20)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protein quantities table along with the associated metadata are provided in supplementary materials. All scripts used to train and assess the machine learning models are likewise provided.